Sign in Subscribe
Drugs

Breakthroughs in Cancer Therapy: Insights from New Studies on Angiogenesis Inhibitors

Strategic Insights

— 2 min read

Scientists in the United States and People's Republic of China have made significant advancements in cancer therapy by exploring novel angiogenesis inhibitors, compounds that can halt the growth of new blood vessels that feed tumors, thereby preventing cancer progression and metastasis. Recent studies have shed light on the potential of doxazosin, Src kinase blockade, and erianin in inhibiting angiogenesis, with the aim of developing more effective treatments for advanced prostate cancer and other cancers.

Key Takeaways:

  • Doxazosin, a quinazoline-derived alpha1-adrenoceptor antagonist, has been shown to induce an anoikis effect in human prostate cancer cells and suppress prostate tumor vascularity (Keledjian and Kyprianou, 2003).
  • Src kinase blockade prevents tumor extravasation and metastasis by stabilizing endothelial barrier function and suppressing the activity of vascular endothelial growth factor (VEGF) (Weis and colleagues, 2004).
  • Erianin, a natural product from Dendrobium chrysotoxum, exhibits potent antiangiogenic activities in vivo and in vitro, causing significant vascular shutdown and tumor necrosis (Gong and colleagues, 2004).
  • Human umbilical vein endothelial cells (HUVECs) were used as an in vitro model to determine the effect of doxazosin on cell growth, apoptosis, adhesion, migration, and angiogenic response of endothelial cells (Keledjian and colleagues, 2005).
  • In vivo studies demonstrated that erianin caused extensive tumor necrosis, growth delay, and rapid vascular shutdown in hepatoma and melanoma models (Gong and colleagues, 2004).
  • The mechanism of action of erianin involves the depolymerization of both F-actin and P-tubulin in proliferating endothelial cells, leading to endothelial cytoskeletal disorganization (Gong and colleagues, 2004).
  • VEGF is a unique angiogenic growth factor that disrupts endothelial barrier function, contributing to tumor cell extravasation and metastasis (Weis and colleagues, 2004).
  • Pharmacological blockade of VEGF, VEGFR-2, or Src stabilizes endothelial barrier function and suppresses tumor cell extravasation in vivo (Weis and colleagues, 2004).

Statistics:

  • 100 mg/kg of erianin caused significant vascular shutdown within 4 hours of administration (Gong and colleagues, 2004).
  • The EC50 of erianin for inhibiting proliferation of human umbilical vein endothelial cells was 34.1 ± 12.7 nM (Gong and colleagues, 2004).
  • The study by Keledjian and colleagues used human umbilical vein endothelial cells (HUVECs) as an in vitro model to study the effect of doxazosin (Keledjian and colleagues, 2005).
  • The study by Weis and colleagues demonstrated a dramatic reduction in tumor cell extravasation in lungs or livers of mice lacking Src or Yes (Weis and colleagues, 2004).

Sources:

  • Keledjian, K., Kyprianou, N. (2003). Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion. J Cell Biochem, 94(2), 374-388.
  • Weis, S., Cui, J., Troussard, A., Babic, A. M., Schwartz, M. A., Cheresh, D. A. (2004). Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol, 167(2), 223-229.
  • Gong, Y. Q., Wang, Z. T., Zhang, X. Y., Lu, Q., Chen, Y. W., Li, Y. Q., ... & Zheng, Y. L. (2004). In vivo and in vitro evaluation of erianin, a novel antiangiogenic agent. Eur J Cancer, 40(10), 1554-1565.

Read more